PUBLISHER: DelveInsight | PRODUCT CODE: 1173617
PUBLISHER: DelveInsight | PRODUCT CODE: 1173617
DelveInsight's "Bullous Pemphigoid (BP) - Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the BP, historical and forecasted epidemiology as well as the BP market trends in the United States, the EU4 and the UK and Japan.
The BP market report provides current treatment practices, emerging drugs, BP market share of the individual therapies, current and forecasted BP market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current BP treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2019-2032.
The DelveInsight's BP market report gives a thorough understanding of the disease. BP is a rare skin condition that mainly affects older people. It usually starts with an itchy, raised rash. As the condition develops, large blisters can form on the skin. It is characterized by a poor prognosis due to its high mortality rate and the tendency to relapse. The relapse rate of BP ranges from 27.87% to 53% after disease remission, while the majority of relapses occur early (within 6 months) during remission. Treatment usually helps heal the blisters and ease any itching.
Pruritus is the first symptom of bullous pemphigoid. Skin lesions may not develop for several years. Often, characteristic tense bullae develop on the skin of the trunk and in the flexural and intertriginous areas. Bullae may develop on normal-appearing skin or may be preceded by erythematous or urticarial-appearing plaques. The localized disease may occur at trauma sites, stomas, and anogenital and lower leg areas.
The diagnosis of BP is based on a combination of clinical features, positive direct immunofluorescence (IF) microscopy of perilesional skin, and the detection of specific circulating IgG anti-basement membrane autoantibodies by either indirect IF microscopy studies or by enzyme-linked immunosorbent assay (ELISA). In the majority of cases, the latter tests are sufficient for a correct diagnosis.
The therapeutic options for BP are divided into anti-inflammatory drugs, immunosuppressive or immunomodulatory drugs, and procedures to remove circulating pathogenic antibodies or inflammatory mediators. The choice of treatment depends on the individual patient's circumstances, especially the severity of the BP and the presence of comorbidities.
The BP epidemiology division provides insights about historical and current BP patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides a historical as well as forecasted BP epidemiology scenario in the 7MM covering the United States, the EU4 and the UK, and Japan from 2019 to 2032.
In 2021, the total diagnosed prevalent cases of BP were approximately 132,200 cases in the 7MM which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted BP epidemiology [segmented as Diagnosed prevalent cases of BP, Gender-specific diagnosed prevalent cases of BP, Age-specific diagnosed prevalent cases of BP, Severity-specific diagnosed prevalent cases of BP, and Total treated cases of BP] in the 7MM covering the United States, the EU4 and the UK, and Japan from 2019 to 2032
The epidemiology segment also provides the BP epidemiology data and findings across the United States, the EU4 and the UK, and Japan.
The drug chapter segment of the BP report encloses the detailed analysis of BP marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the BP clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
The report provides the details of the emerging therapies under the late and mid-stage of development for BP treatment.
BP market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted BP market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.
This segment gives a thorough detail of the BP market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the BP market in 7MM is expected to witness a major change in the study period 2019-2032.
The BP market size in the 7MM is expected to change during the study period 2019-2032. The therapeutic market of BP in the seven major markets is expected to increase during the study period (2019-2032). In 2021, the total market size of BP was USD 171.25 million which is expected to rise during the study period (2019-2032).
The total market size of BP in the United States accounted for USD 55.08 million in 2021 which is expected to rise during the study period (2019-2032).
In the EU4 and the UK, the total market size of BP was USD 107 million in 2021, which is expected to rise during the study period (2019-2032).
In Japan, the total market size of BP was USD 8.86 million in 2021, which is expected to rise during the study period (2019-2032).
This section focuses on the rate of uptake of the potential drugs recently launched in the BP market or expected to get launched in the market during the study period 2019-2032. The analysis covers BP market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, and reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Bullous Pemphigoid (BP) Development Activities
The report provides insights into different therapeutic candidates in the Phase II, and Phase III stages. It also analyses BP key players involved in developing targeted therapeutics.
The report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information for BP emerging therapies.
To keep up with current market trends, we take KOLs and SMEs ' opinions working in the BP domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or BP market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
We perform Competitively and Market Intelligence analysis of the BP Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.